It’s a no brainer just to do a single European trial if the FDA asks for two. Management needs to communicate this better to the market, The FDA decision is a setback but at the moment it is being treated by investors as a success v failure decision.
Ann: Invex Granted Type C Meeting with FDA, page-112
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 16.12pm 15/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable